Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FV-LDP-D3-AE
- Development stage
- Preclinical
- Lead developer
- Chinese Academy of Medical Sciences Peking Union Medical College
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
FV-LDP-D3-AE is a recombinant antibody-drug conjugate designed for targeted cancer therapy. It consists of a single-chain variable fragment (scFv) of an anti-EGFR antibody, the apoprotein of lidamycin (LDP), and the third domain of human serum albumin (D3), to which the enediyne chromophore (AE) of lidamycin is conjugated. FV-LDP-D3-AE binds specifically to EGFR-overexpressing cancer cells, inhibits EGFR phosphorylation, downregulates IMPDH2 expression, induces apoptosis and DNA damage, causes G2/M cell cycle arrest, and results in mitochondrial damage. The drug enters cancer cells via intensive macropinocytosis, exhibiting high potency against esophageal, pancreatic, and colorectal cancers in preclinical models. Its mechanism combines EGFR-targeted delivery with the cytotoxic action of lidamycin enediyne[1][3][6].
- Brand names
- FV-LDP-D3-AEFV-LDP-D-3-AEFV-LDP-D 3-AE
- Other names
- FV-LDP-D3-AEFV-LDP-D-3-AEFV-LDP-D 3-AE
02
Targets
EGFR (Epidermal growth factor receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)TERT (Telomerase)
Beyond the preview
Go deeper on FV-LDP-D3-AE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FV-LDP-D3-AE.